Global pharmacogenomics: Distribution of CYP3A5 polymorphisms and phenotypes in the Brazilian population

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Suarez Kurtz, Guilherme ^a   Vargens, Daniela D ^a   Santoro, Ana Beatriz ^a   Hutz, Mara H ^b   De Moraes, Maria Elisabete ^c   Pena, Sérgio D J ^d   Ribeiro dos Santos, Ândrea ^e   Romano Silva, Marco A ^d   Struchiner, Claudio José ^f  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^d FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^e FEDERAL UNIVERSITY OF PARÁ   (Brazil)

^f INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AFRICA; ALLELE; ARTICLE; BRAZIL; BROWN RACE; CAUCASIAN; COHORT ANALYSIS; CYP3A5 GENE; DNA POLYMORPHISM; EUROPE; GENE FREQUENCY; GENETIC HETEROGENEITY; GENETIC VARIABILITY; GEOGRAPHIC DISTRIBUTION; HAPLOTYPE; HUMAN; NEGRO; PHARMACOGENOMICS; PHENOTYPE; POPULATION GENETIC STRUCTURE; RACE; RACE DIFFERENCE; SKIN COLOR; WESTERN HEMISPHERE;

ALLELES; BRAZIL; COHORT STUDIES; CYTOCHROME P-450 CYP3A; ETHNIC GROUPS; GENE FREQUENCY; GENOTYPE; HAPLOTYPES; HUMANS; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, GENETIC;

EID: 84897489411     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0083472     Document Type: Article

References (27)

1. Zanger UM, Schwab M (2013) Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 138: 103-141.
2. Lamba J, Hebert JM, Schuetz EG, Klein TE, Altman RB (2012) PharmGKB summary: very important pharmacogene information for CYP3A5. Pharmacogenet Genomics 22: 555-558.
3. Lee SJ, Goldstein JA (2005) Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests. Pharmacogenomics 6: 357-371.
4. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, et al. (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27: 383-391 (Pubitemid 32268418)
5. International HapMap Project website. Available: http://hapmap.ncbi.nlm. nih.gov. Accessed 2013 Jun 10.
6. Hustert E, Haberl M, Burk O, Wolbold R, He YQ, et al. (2001) The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11:773-779. (Pubitemid 33151512)
7. Garsa AA, McLeod HL, Marsh S (2005) CYP3A4 and CYP3A5 genotyping by pyrosequencing. BMC Med Genet 6: 19.
8. Dandara C, Ballo R, Parker MI (2005) CYP3A5 genotypes and risk of oesophageal cancer in two South African populations. Cancer Lett 225: 275-282. (Pubitemid 40835875)
9. Mirghani RA, Sayi J, Aklillu E, Allqvist A, Jande M, et al. (2006) CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population. Pharmacogenet Genomics 16: 637-645. (Pubitemid 44223075)
10. Suarez-Kurtz G, Perini JA, Bastos-Rodrigues L, Pena SD, Struchiner C (2007) Impact of population admixture on the distribution of the CYP3A5*3 polymorphism. Pharmacogenomics 8: 1299-1306. (Pubitemid 350162846)
11. Instituto Brasileiro de Geografia e Estatística website. Available: http://www.ibge.gov.br. Accessed 2013 Jun 10.
12. Instituto Brasileiro de Geografia e Estatística website. Available: http://www.sidra.ibge.gov.br/bda/tabela/listabl.asp?z=t&c=262. Accessed 2013 Jun 10.
13. Bastos-Rodrigues L, Pimenta JR, Pena SDJ (2006) The genetic structure of human populations studied through short insertion-deletion polymorphisms. Ann Human Genet 70: 658-665. (Pubitemid 44173374)
14. Pritchard JK, Stephens M, Donnelly P (2000) Inference of population structure using multilocus genotype data. Genetics 155: 945-959. (Pubitemid 30397141)
15. Mayo Clinic website. Available: http://www.mayo.edu/research/documents/ manualhaplostatspdf/DOC-10026895 Accessed 2013 May 25.
16. Santoro A, Felipe CR, Tedesco-Silva H, Medina-Pestana JO, Struchiner CJ, et al. (2011) Pharmacogenetics of calcineurin inhibitors in Brazilian renal transplant patients. Pharmacogenomics 12: 1293-1303.
17. Venables WN, Ripley BD (2002) Modern Applied Statistics with S. Fourth edition. New York: Springer.
18. Suarez-Kurtz G, Amorim A, Damasceno A, Hutz MH, de Moraes MO, et al. (2010) VKORC1 polymorphisms in Brazilians: comparison with the Portuguese and Portuguese-speaking Africans and pharmacogenetic implications. Pharmacogenomics 11: 1257-1267.
19. Suarez-Kurtz G, Genro JP, de Moraes MO, Ojopi EB, Pena SD, et al. (2012) Global pharmacogenomics: Impact of population diversity on the distribution of polymorphisms in the CYP2C cluster among Brazilians. Pharmacogenomics J 12: 267-276.
20. R Development Core Team (2009) R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing.
21. Fox J, Weisberg S (2011) An R Companion to Applied Regression. Second Edition. Thousand Oaks, CA: SAGE Publications.
22. Pena SDJ, Di-Pietro G, Fuchshuber-Moraes M, Genro JP, Hutz MH, et al. (2011) The genomic ancestry of individuals from different geographical regions of Brazil is more uniform than expected. PLoS One Feb 16, 6(2):e17063.
23. Suarez-Kurtz G (2010) Pharmacogenetics in the Brazilian population. Frontiers in Pharmacogenetics 1, article 118, 1-10,
24. Sortica VdeA, Ojopi EB, Genro JP, Callegari-Jacques S, Ribeiro-Dos-Santos A, et al. (2012) Influence of genomic ancestry on the distribution of SLCO1B1, SLCO1B3 and ABCB1 gene polymorphisms among Brazilians. Basic Clin Pharmacol Toxicol 110: 460-468.
25. Ferreira PE, Veiga MI, Cavaco I, Martins JP, Andersson B, et al. (2008) Polymorphism of antimalaria drug metabolizing, nuclear receptor, and drug transport genes among malaria patients in Zanzibar, East Africa. Ther Drug Monit 30:10-15. (Pubitemid 351161093)
26. Salzano FM, Bortolini MC (2002) The evolution and genetics of Latin American populations, Cambridge: Cambridge University Press, 512 p.
27. Suarez-Kurtz G, Pena SDJ (2006) Pharmacogenomics in the Americas: Impact of genetic admixture. Curr Drug Targets 7: 1649-1658. (Pubitemid 44873727)